ResMed Inc. 10-Q Summary: Quarter Ended September 30, 1996
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 1996, for ResMed Inc., a Delaware corporation and holding company for ResCare Holdings Ltd. The company designs, manufactures, and markets devices for the evaluation and treatment of sleep-disordered breathing, primarily obstructive sleep apnea. Principal manufacturing is located in Australia, with major distribution and sales sites in the United States, United Kingdom, and Europe.
Key Financial Metrics
| Metric | Q1 1997 (Sep 30, 1996) | Q1 1996 (Sep 30, 1995) |
|---|---|---|
| Net Revenues | $11,141,000 | $6,703,000 |
| Gross Profit | $6,291,000 | $3,491,000 |
| Gross Margin | 56% | 52% |
| Operating Income | $1,578,000 | $681,000 |
| Net Income | $1,840,000 | $880,000 |
| Diluted EPS | $0.25 | $0.12 |
| Cash from Operations | $1,783,000 | ($1,188,000) |
| Cash and Equivalents | $6,455,000 | $2,449,000 |
| Working Capital | $31,450,000 | N/A |
| Total Debt (Current + Long-term) | $889,000 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 66% to $11.1 million, driven by higher unit sales in North America and Europe. European revenue surged to $5.4 million from $1.9 million, significantly aided by the acquisition of the Priess business in Germany in February 1996.
- Profitability: Gross profit rose 80% to $6.3 million, with margins expanding from 52% to 56% due to a shift toward higher-margin products and improved European performance.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 84% to $3.9 million. This was primarily due to an increase in sales and administrative personnel (from 70 to 88) and a rise in legal costs from $61,000 to $327,000 related to ongoing litigation.
- Other Income: Other income, net, more than doubled to $1.1 million, largely due to $750,000 in net foreign exchange gains from marking to market currency option contracts.
- Cash Flow: Operating cash flow turned positive, generating $1.8 million compared to a $1.2 million usage in the prior year, reflecting increased profitability offset by higher accounts receivable.
Outlook, Risks, and Contingencies
Management Commentary: Management attributes the strong performance to the Priess acquisition and increased unit sales. The effective tax rate increased to approximately 32% from 28%, primarily due to higher German corporate taxation rates, partially offset by Australian R&D tax deductions.
Risks and Contingencies:
- Legal Proceedings: The company is involved in significant patent litigation. In Australia, a patent was revoked on appeal, with $300,000 accrued for associated costs. In the U.S., ResMed is suing Respironics for patent infringement, while Respironics has countersued claiming invalidity. Additionally, Respironics and its Australian distributor have filed a claim in Australia alleging unfair trade practices and misuse of market power, seeking approximately $901,000 in damages. Management believes these actions will not have a material adverse effect but notes ongoing legal costs and uncertainty.
- Foreign Exchange: The company is exposed to currency fluctuations affecting international sales and manufacturing costs. It manages this risk through foreign currency option contracts with notional amounts totaling approximately $41.7 million.
- Government Grants: Australian Federal Government export grants have been terminated, though this was marginally offset by increased manufacturing and research activity grants.
Key Facts for Investor Verification
- Verify the status and potential financial impact of the ongoing patent litigation with Respironics in both the U.S. and Australia, including the $901,000 damage claim.
- Confirm the sustainability of the 56% gross margin, which was boosted by the Priess acquisition and a shift to higher-margin products.
- Monitor the impact of the terminated Australian export grants on future revenue streams.
- Assess the exposure to foreign exchange rate fluctuations given the company's significant international operations and reliance on hedging instruments.
- Review the capital lease obligation of $19,000 entered into during the quarter for computer equipment.